Features of the Course of Metapneumoviral Infection in Adults
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to determine the clinical features of metapneumovirus infection in adults and to determine the effect of coinfection on the severity of the course.
Materials and methods. Bibliosemantic and analytical methods were used for this work. Recent scientific publications of such electronic databases as PubMed, Skopus, Cochrane have been analyzed.
Results. The prevalence of metapneumovirus infection is 4–13%. Although most children are infected with HMPV by the age of 5, reinfection is possible throughout adulthood. HMPV was detected in 13% of hospitalized adults with acute respiratory disease inRochester,New York. Clinical manifestations of HMPV infection are diverse. Most common symptoms are bronchiolitis, pneumonia, exacerbation of bronchial asthma. The incidence of viral coinfection is from 6 to 23%.
Conclusions. HMPV-infection has a mild course in healthy young people, but in the elderly, with concomitant pathology, has a more severe course and is characterized by higher mortality. Coinfection with other viruses or bacteria can worsen the patient’s symptoms and condition, but the severity of the disease does not seem to be affected.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
van den Hoogen BG, de Jong JC, Groen J, et al.: A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–24. 10.1038/89098
Biacchesi S, Skiadopoulos MH, Yang L, et al.: Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol. 2004;78(23):12877–87. 10.1128/JVI.78.23.12877-12887.2004
Chang A, Masante C, Buchholz UJ, et al.: Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol.2012;86(6):3230–43. 10.1128/JVI.06706-11
Derdowski A, Peters TR, Glover N, et al.: Human metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirements for inclusion body formation. J Gen Virol. 2008;89(Pt 11):2698–708. 10.1099/vir.0.2008/004051-0
Fearns R, Collins PL: Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol. 1999;73(7):5852–64.
Ren J, Wang Q, Kolli D, et al.: Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS. J Virol. 2012;86(23):13049–61. 10.1128/JVI.01248-12
Masante C, El Najjar F, Chang A, et al.: The human metapneumovirus small hydrophobic protein has properties consistent with those of a viroporin and can modulate viral fusogenic activity. J Virol.2014;88(11):6423–33. 10.1128/JVI.02848-13
Thammawat S, Sadlon TA, Hallsworth PG, et al.: Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol. 2008;82(23):11767–74. 10.1128/ JVI.01208-08
Shafagati N, Williams J. Human metapneumovirus – what we know now. F1000Res. 2018; 7:135. Published 2018 Feb 1. doi:10.12688/ f1000 research.12625.1
El Najjar F, Cifuentes-Muñoz N, Chen J, et al.: Human metapneumovirus Induces Reorganization of the Actin Cytoskeleton for Direct Cell-to-Cell Spread. PLoS Pathog. 2016;12(9):e1005922. 10.1371/journal.ppat.1005922
Thammawat S, Sadlon TA, Hallsworth PG, et al.: Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol. 2008;82(23):11767–74. 10.1128/JVI.01208-08
Hamelin ME, Couture C, Sackett M, et al. : The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antivir Ther. 2008;13(1):39–46
Falsey AR, Hennessey PA, Formica MA, et al. :Humoral immunity to human metapneumovirus infection in adults. Vaccine. 2010;28(6):1477–80. 10.1016/j.vaccine.2009.11.063
van den Hoogen BG, Herfst S, Sprong L, et al. : Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis. 2004;10(4):658–66. 10.3201/eid1004.030393
MacPhail M, Schickli JH, Tang RS, et al. : Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J Gen Virol. 2004;85(Pt 6):1655–63. 10.1099/vir.0.79805-0
Yang CF, Wang CK, Tollefson SJ, et al. : Human metapneumovirus G protein is highly conserved within but not between genetic lineages. Arch Virol. 2013;158(6):1245–52. 10.1007/s00705-013
McDougall JS, Cook JK: Turkey rhinotracheitis: preliminary investigations. Vet Rec. 1986;118(8):206–7. 10.1136/vr.118.8.206
Easton AJ, Domachowske JB, Rosenberg HF: Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev. 2004;17(2):390–412. 10.1128/CMR.17.2.390-412.2004
Juhasz K, Easton AJ: Extensive sequence variation in the attachment (G) protein gene of avian pneumovirus: evidence for two distinct subgroups. J Gen Virol. 1994;75(Pt 11):2873–80. 10.1099/0022-1317-75-11-2873
Aberle J.H., Aberle S.W., Redlberger-Fritz M., Sandhofer M.J., Popow-Kraupp T. 2010. Human metapneumovirus subgroup changes and seasonality during epidemics. Pediatr. Infect. Dis. J. 29:1016–1018
Ditt V., Lusebrink J., Tillmann R.L., Schildgen V., Schildgen O. 2011. Respiratory infections by HMPV and RSV are clinically indistinguishable but induce different host response in aged individuals. PLoS One 6:e16314.
Lusebrink J., et al. High seroprevalence of neutralizing capacity against human metapneumovirus in all age groups studied in Bonn, Germany. Clin. Vaccine Immunol. 17:481–484
Williams JV, Edwards KM, Weinberg GA, et al. : Population-based incidence of human metapneumovirus infection among hospitalized children. J Infect Dis. 2010;201(12):1890–8. 10.1086/652782
Walsh EE, Peterson DR, Falsey AR: Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med. 2008;168(22):2489–96. 10.1001/archinte.168.22.2489
Honda H., et al. 2006. Outbreak of human metapneumovirus infection in elderly inpatients in Japan. J. Am. Geriatr. Soc. 54:177–180
Darniot M., Petrella T., Aho S., Pothier P., Manoha C. 2005. Immune response and alteration of pulmonary function after primary human metapneumovirus (hMPV) infection of BALB/c mice. Vaccine23:4473–4480
Vargas S.O., Kozakewich H.P., Perez-Atayde A.R., McAdam A.J. 2004. Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus. Pediatr. Dev. Pathol. 7:478–486
Beneri C., Ginocchio C.C., Manji R., Sood S. 2009. Comparison of clinical features of pediatric respiratory syncytial virus and human metapneumovirus infections. Infect. Control Hosp. Epidemiol. 30:1240–1241
Howard LM, Edwards KM, Zhu Y, et al.: Clinical Features of Human Metapneumovirus Infection in Ambulatory Children Aged 5–13 Years. J Pediatric Infect Dis Soc. 2017. 10.1093/jpids/pix012
Williams JV, Harris PA, Tollefson SJ, et al. : Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350(5):443–50. 10.1056/NEJMoa025472
van den Hoogen B.G., Osterhaus D.M., Fouchier R.A. 2004. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr. Infect. Dis. J. 23:S25–S32
Williams JV, Crowe JE, Jr, Enriquez R, et al. :Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis. 2005;192(7):1149–53. 10.1086/444392
Boivin G, Abed Y, Pelletier G, et al. : Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis. 2002;186(9):1330–4. 10.1086/344319
Boeckh M., Erard V., Zerr D., Englund J. 2005. Emerging viral infections after hematopoietic cell transplantation. Pediatr. Transplant. 9(Suppl. 7):48–54
Williams J.V., et al. 2005. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J. Infect. Dis.192:1061–1065
Cane P.A., van den Hoogen B.G., Chakrabarti S., Fegan C.D., Osterhaus A.D. 2003. Human metapneumovirus in a haematopoietic stem cell transplant recipient with fatal lower respiratory tract disease. Bone Marrow Transplant. 31:309–310
van den Hoogen B.G. 2007. Respiratory tract infection due to human metapneumovirus among elderly patients. Clin. Infect. Dis. 44:1159–1160
Vicente D., Montes M., Cilla G., Perez-Trallero E. 2004. Human metapneumovirus and chronic obstructive pulmonary disease. Emerg. Infect. Dis. 10:1338–1339
Boivin G., et al. 2007. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin. Infect. Dis. 44:1152–1158
Ginocchio C.C., Manji R., Lotlikar M., Zhang F. 2008. Clinical evaluation of NucliSENS magnetic extraction and NucliSENS analyte-specific reagents for realtime detection of human metapneumovirus in pediatric respiratory specimens. J. Clin. Microbiol. 46:1274–1280
Tollefson SJ, Cox RG, Williams JV: Studies of culture conditions and environmental stability of human metapneumovirus. Virus Res. 2010;151(1):54–9. 10.1016/j.virusres.2010.03.018
Wyde P.R., Chetty S.N., Jewell A.M., Boivin G., Piedra P.А. 2003. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 60:51–59
